Anti-VGCC negative and Anti-SOX1 positive Lambert-Eaton myasthenic syndrome as the initial presentation of small cell lung cancer: a case report - Scorecard - MDSpire
Advertisement
Anti-VGCC negative and Anti-SOX1 positive Lambert-Eaton myasthenic syndrome as the initial presentation of small cell lung cancer: a case report
Clinical Scorecard: Initial Presentation of Small Cell Lung Cancer Manifesting as Anti-SOX1 Positive and Anti-VGCC Negative Lambert-Eaton Myasthenic Syndrome: A Case Study
At a Glance
Category
Detail
Condition
Lambert-Eaton Myasthenic Syndrome (LEMS)
Key Mechanisms
Impaired acetylcholine release at the neuromuscular junction
Target Population
Patients with suspected LEMS, particularly those with risk factors for small cell lung cancer
Care Setting
Oncology and neurology clinics
Key Highlights
LEMS can manifest as a paraneoplastic syndrome, particularly associated with small cell lung cancer (SCLC).
Anti-SOX1 antibodies are significant for diagnosing SCLC in patients negative for anti-VGCC antibodies.
The DELTA-P score aids in assessing malignancy risk in patients presenting with LEMS-like symptoms.
A total DELTA-P score of ≥ 3 is highly indicative of concurrent SCLC.
Early detection and treatment can lead to improved outcomes, as demonstrated in the case study.
Guideline-Based Recommendations
Diagnosis
Test for anti-VGCC and anti-SOX1 antibodies in patients with suspected LEMS.
Management
Initiate standard antitumor therapy upon confirmation of SCLC.
Monitoring & Follow-up
Regular clinical and radiological screening for early tumor detection in high-risk patients.
Risks
LEMS may precede the diagnosis of underlying malignancies, complicating timely treatment.
Patient & Prescribing Data
Older adults, particularly males with a history of smoking.
Standard antitumor therapy can lead to significant improvement in muscle weakness.
Clinical Best Practices
Utilize the DELTA-P score for malignancy screening in patients with LEMS.
Consider anti-SOX1 antibody testing in atypical LEMS presentations.
